Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

SHOCKING: Looking into neurocrine biosciences s return on capital employed - You Need To See This

Benzinga Pro data, Neurocrine Biosciences (NASDAQ:NBIX) reported Q4 sales of $312.00 million. Earnings fell to a loss of $7.30 million, resulting in a 132.44% decrease from last quarter. In Q3, Neurocrine Biosciences earned $22.50 million and total sales reached $296.00 million.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.